Cleared Traditional

ENTEROVIRUS 71 MONOCLONAL ANTIBODY (K940473) - FDA 510(k) Clearance

Class I Microbiology device.

K940473 · Chemicon Intl., Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1995
Decision
587d
Days
Class 1
Risk

K940473 is an FDA 510(k) clearance for the ENTEROVIRUS 71 MONOCLONAL ANTIBODY. Classified as Antisera, Fluorescent, Poliovirus 1-3 (product code GOE), Class I - General Controls.

Submitted by Chemicon Intl., Inc. (Temecula, US). The FDA issued a Cleared decision on September 12, 1995 after a review of 587 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3405 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Microbiology submissions.

View all Chemicon Intl., Inc. devices

Submission Details

510(k) Number K940473 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 02, 1994
Decision Date September 12, 1995
Days to Decision 587 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
485d slower than avg
Panel avg: 102d · This submission: 587d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GOE Antisera, Fluorescent, Poliovirus 1-3
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.3405
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.